ผศ.พญ.ธัญนันท์ เรืองเวทย์วัฒนา ... career...
Embed Size (px)
TRANSCRIPT
ผศ.พญ.ธัญนันท์ เรืองเวทย์วัฒนา และ ผศ.พญ. กฤตยิา กอไพศาล
? ?? ??? ????
ORAL PRESENTATION AT WCLC 2011 30 YEARS LYMPHOEPITHELIOMA LUNG CANCER AT MAYO CLINIC
ASCO 2012
WCLC 2013
• "For Houston life" 😘 😘
“I never tried to understand what work-life balance is .... until I came here”
Staying in the quiet places and being with myself, I heard my voices/my thoughts. I held my life in my hand and it was my own. I also restored my heart and made it
fresh again. 😘😘Future is clearer😘😘
I had a chance to change my focus from working to serving my soul. The best part was not about how many projects I have done but it was about the meaning of life
and the future that I have started thinking about it.
Thanks everyone for coming into this chapter of my life.
I will remember all the memories we have shared in the deepest part of my heart.
I will also smile when I look back over this time.
“It has been such a wonderful experience with such a great group of people here”
# Time to go back to my real life 😘 😘
Development of lung cancer treatment in Ramathibodi
Hospital
Translational Science
Bench Work
Network : International & Domestic multicenters
Infrastructure : CRC
Drug Development
in Thailand
Clinic : Multidisciplin
ary team (RLC)
Development of lung cancer treatment in Ramathibodi
Hospital
Translational Science
Bench Work
Network : International & Domestic multicenters
Infrastructure: CRC
Drug Development
in Thailand
Clinic : Multidisciplin
ary team
Multidisciplinary team
1st MDT: 7th October, 2014
Ramathibodi Lung Cancer Consortium (RLC)
ตัวช้ีวดั
เป้าหมาย
ผลด าเนินการ ก่อนจัดตั้ง
RLC
(control) N=81
หลงัจัดตั้ง RLC
N = 200
P-value
Time from first visit to first intervention (median, days)
ลดเวลา
11
2
<0.001 HR=2.01
95%CI; 1.53-2.62
Time from first visit to first treatment (median, days)
ลดเวลา
57
14
<0.001 HR=2.93
95%CI; 2.21-3.89
Number visits from first visit to first treatment (mean +- SD, days)
ลดจ านวน visits
7.98 ± 4.47
2.27 ± 2.70
<0.001
ผลการด าเนินงานและตัวชีว้ัดทมี RLC
ตัวช้ีวดั ALL CONTROL RLC P
Time from 1st visit to 1st imaging study
All N=53
Control N=14
RLC
N=39
Median (days) 7 12.5 6 0.649
Time from 1st visit to 1st biopsy
All N=38
Control N=27
RLC
N=11
Median (days) 14.5 20 2 0.004
Time from 1st visit to surgery All N=71
Control N=26
RLC
N=45
Median (days) 50 77 31 <0.001
Time from 1st visit to 1st Chemotherapy
All N=93
Control N=32
RLC
N=61
Median (days) 20 45 11 <0.001
Time from 1st visit to 1st radiation
All N=33
Control N=10
RLC
N=23
Median (days) 16 19 13 0.247
0.0
00.2
50.5
00.7
51.0
0
0 2 4 6
time (years)
Control RLC
Kaplan-Meier survival estimates
Overall survival rate & time
P-value <0.001 variable
5-year OS rate (%) and mOS (years) P-value
5-year OS rate <0.001
control 33.1
(22.5-44.0)
RLC 45.9
(23.1-66.1)
median survival (years)
<0.001
control
1.5
RLC 4.7
0.0
00.2
50.5
00.7
51.0
0
0 2 4 6
time (years)
Control RLC
Kaplan-Meier survival estimatesStage I-II
0.0
00
.25
0.5
00
.75
1.0
0
0 1 2 3 4 5
time (years)
Control RLC
Kaplan-Meier survival estimatesStage III-IV
HR = 0.32 (0.2-0.5), P<0.001 mOS RLC = 2.9 years mOS control = 0.6 years
• รางวัลชนะเลิศงานพัฒนาคุณภาพ คณะแพทยศ่าสตร์โรงพยาบาลรามาธิบดี เดือน สงิหาคม 2017 • รางวัลชนะเลศิ Team Good Practice ของมหาวทิยาลัยมหดิล เดือน พฤศจกิายน 2017
Prevention
Smoking
Biomarker causing lung cancer
Drugs prevent lung cancer
Bench works
Biomarker
Pathway for lung cancer prevention and
treatment
How to overcome resistance and decrease
AE of targeted drug ?
New effective chemotherapy
Treatment
Clinical trial design
Proper endpoints and biomarkers
Molecular testing
Cooperative network in each region
Targeted Therapy
“Bench to Bedside
Clinical Study”
Drug Discovery and
Development
Changing the Cancer
Treatment Paradigm
PROPOSED CONCEPTS FOR LUNG CANCER RESEARCH
AND CANCER DRUG DEVELOPMENT
Cooperation
Ramathibodi & University-based hospitals
Ramathibodi Lung Cancer Consortium (RLC)
Center for Medical Genomics
Ramathibodi Cancer Center and Biobank
• Molecular alteration in Thai population • Development of diagnostic techniques both in tissue and liquid biopsy • Drug Development
Journal of Thoracic Oncology Vol. 11 No. 5: 613-638
Development of lung cancer treatment in Ramathibodi
Hospital
Translational Science
Bench Work
Network : International &
Domestic multicenters
Infrastructure
Drug Development in
Thailand
Clinic : Multidisciplinary
team
• Lung Cancer Group (RA, CU, SI, Rajavithee)
• Research cooperation (RA, CU, SI, Rajavithee, PM, Songkla, CM)
Thailand Network
• USA
• Japan, Hongkong, Singapore, Taiwan, Korea
International Network
Management in locally advanced and advanced NSCLC : MDT discussion with Dr. Alex Adjei 10 April 2015
2010 RAMATHIBODI-MAYO JOINT CONFERENCE: Update in cancer treatment
12-13 March, 2010 Pullman Hotel, Bangkok
100 Pharmacogenes -next generation sequencing in chemotherapy treated patients.
Development of lung cancer treatment in Ramathibodi
Hospital
Translational Science
Bench Work
Network : International &
Domestic multicenters
Infrastructure
Drug Development in
Thailand
Clinic : Multidisciplinary
team
https://www.conquer.org/grants-awards/funding-opportunities
http://www.esmo.org/Career-Development/Oncology-
Fellowships/Fellowship-Offers
Grants Durations Award
1. Translational Research Unit Visits
3-4 days 1,000 Euro
2. ESMO European Integration Fellowship
6 weeks 5,000 Euro
3. ESMO Palliative Care Fellowships
1-3 months
5,000 Euro
4. ESMO Translational Research 1 year 40,000 Euro
5. ESMO Clinical Research Fellowships
1 year 40,000 Euro
6. Clinical Unit Visits 6 weeks 5,000 Euro
7. Travel grants for ESMO young oncologists
ESMO meeting
Travel grants
http://www.esmo.org/Career-Development/Oncology-Fellowships/Fellowship-
Offers
https://www.iaslc.org/fellowship/announcements
The best results will be realised when we all work together (Multicenter)
Oncologists Pathologists
Pulmonologists
Surgeons
Radiation oncologists Nurses
Patients + Thailand
Molecular pathologists
Radiologists
Cytologists
Pharmacist
Nuclear medicine
